This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


Drugmaker settles US Zantac cancer case

Credit: CC0 Public Domain

British pharmaceutical group GlaxoSmithKline said Friday it has settled a US lawsuit which had alleged heartburn drug Zantac caused cancer, but admitted no liability.

GSK "has reached a confidential settlement with James Goetz, and the case he filed in California state court... will be dismissed", it said in a statement.

"The settlement reflects the company's desire to avoid distraction related to protracted litigation in this case." The court case had been due to start in one month.

"GSK does not admit any in this and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases," the company added.

Over-the-counter drug Zantac, whose is ranitidine, has also been manufactured by French peer Sanofi.

Zantac has been removed from the North American market.

Last year, GSK revealed it was facing about 3,000 individual and class-action lawsuits over Zantac in the United States, with proceedings underway in Canada and Israel.

Friday's news sent GSK's share price rallying six percent to £14.40 on London's top-tier FTSE 100 index, which was down overall in midday deals.

© 2023 AFP

Citation: Drugmaker settles US Zantac cancer case (2023, June 23) retrieved 10 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Drugmaker shares rally on US cancer ruling over Zantac


Feedback to editors